abiraterone has been researched along with hydroxyflutamide in 1 studies
| Studies (abiraterone) | Trials (abiraterone) | Recent Studies (post-2010) (abiraterone) | Studies (hydroxyflutamide) | Trials (hydroxyflutamide) | Recent Studies (post-2010) (hydroxyflutamide) |
|---|---|---|---|---|---|
| 942 | 97 | 854 | 288 | 5 | 55 |
| Protein | Taxonomy | abiraterone (IC50) | hydroxyflutamide (IC50) |
|---|---|---|---|
| Progesterone receptor | Homo sapiens (human) | 2.013 | |
| Androgen receptor | Homo sapiens (human) | 0.9313 | |
| Androgen receptor | Mus musculus (house mouse) | 0.6073 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Endo, S; Fujii, S; Fujimoto, N; Gouda, H; Hu, D; Iguchi, K; Ikari, A; Irie, K; Kawai, M; Matsukawa, T; Matsunaga, T; Nakayama, T; Oguri, H; Okada, T; Segawa, J; Toyooka, N; Xia, S | 1 |
1 other study(ies) available for abiraterone and hydroxyflutamide
| Article | Year |
|---|---|
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
Topics: Aldo-Keto Reductase Family 1 Member C3; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Design; Enzyme Inhibitors; G1 Phase Cell Cycle Checkpoints; Humans; Male; Mice, Inbred BALB C; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; Xenograft Model Antitumor Assays | 2020 |